Alterity Therapeutics Stock Beta
| ATHE Stock | USD 1.06 0.01 0.95% |
Alterity Therapeutics fundamentals help investors to digest information that contributes to Alterity Therapeutics' financial success or failures. It also enables traders to predict the movement of Alterity Stock. The fundamental analysis module provides a way to measure Alterity Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Alterity Therapeutics stock.
Alterity | Beta |
Alterity Therapeutics Company Beta Analysis
Alterity Therapeutics' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Alterity Therapeutics Beta | 0.68 |
Most of Alterity Therapeutics' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Alterity Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Alterity Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Alterity Therapeutics is extremely important. It helps to project a fair market value of Alterity Stock properly, considering its historical fundamentals such as Beta. Since Alterity Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Alterity Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Alterity Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Alterity Therapeutics has a Beta of 0.684. This is 20.47% lower than that of the Biotechnology sector and 50.79% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Alterity Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Alterity Therapeutics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Alterity Therapeutics could also be used in its relative valuation, which is a method of valuing Alterity Therapeutics by comparing valuation metrics of similar companies.Alterity Therapeutics is currently under evaluation in beta category among its peers.
Alterity Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Alterity Therapeutics from analyzing Alterity Therapeutics' financial statements. These drivers represent accounts that assess Alterity Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Alterity Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 15.2M | 47.5M | 31.3M | 17.0M | 18.2M | 17.3M | |
| Enterprise Value | 6.0M | 19.5M | (3.4M) | 1.4M | 5.8M | 5.5M |
Alterity Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Alterity Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Alterity Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Alterity Therapeutics' value.| Shares | Coppell Advisory Solutions Llc | 2024-06-30 | 5.0 | Ubs Group Ag | 2024-06-30 | 2.0 | Xtx Topco Ltd | 2024-06-30 | 0.0 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 96.8 K | Hb Wealth Management, Llc | 2024-09-30 | 23.8 K | Susquehanna International Group, Llp | 2024-06-30 | 23.3 K | Citadel Advisors Llc | 2024-09-30 | 11.5 K | Twin Lakes Capital Management, Llc | 2024-06-30 | 5.9 K | Providence Capital Advisors, Llc | 2024-06-30 | 200 | Advisor Group Holdings, Inc. | 2024-06-30 | 81.0 | Ronald Blue Trust, Inc. | 2024-09-30 | 40.0 |
As returns on the market increase, Alterity Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Alterity Therapeutics is expected to be smaller as well.
Alterity Fundamentals
| Return On Equity | -1.04 | ||||
| Return On Asset | -0.53 | ||||
| Operating Margin | (6.13) % | ||||
| Current Valuation | 2.13 M | ||||
| Shares Outstanding | 8.74 M | ||||
| Shares Owned By Institutions | 1.28 % | ||||
| Number Of Shares Shorted | 3.57 K | ||||
| Price To Earning | (4.84) X | ||||
| Price To Book | 1.02 X | ||||
| Price To Sales | 2.55 X | ||||
| Revenue | 4.02 M | ||||
| Gross Profit | 3.63 M | ||||
| EBITDA | (19.57 M) | ||||
| Net Income | (19.12 M) | ||||
| Cash And Equivalents | 34.81 M | ||||
| Cash Per Share | 0.87 X | ||||
| Total Debt | 159.04 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 7.07 X | ||||
| Book Value Per Share | 0 X | ||||
| Cash Flow From Operations | (12.61 M) | ||||
| Short Ratio | 0.32 X | ||||
| Earnings Per Share | (1.84) X | ||||
| Target Price | 7.0 | ||||
| Number Of Employees | 10 | ||||
| Beta | 0.68 | ||||
| Market Capitalization | 10.24 M | ||||
| Total Asset | 19.22 M | ||||
| Retained Earnings | (214.16 M) | ||||
| Working Capital | 13.66 M | ||||
| Current Asset | 14.26 M | ||||
| Current Liabilities | 1.73 M | ||||
| Net Asset | 19.22 M |
About Alterity Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alterity Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alterity Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alterity Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Alterity Therapeutics is a strong investment it is important to analyze Alterity Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Alterity Therapeutics' future performance. For an informed investment choice regarding Alterity Stock, refer to the following important reports:Check out Alterity Therapeutics Piotroski F Score and Alterity Therapeutics Altman Z Score analysis. For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alterity Therapeutics. If investors know Alterity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alterity Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.84) | Revenue Per Share 0.6 | Quarterly Revenue Growth 0.384 | Return On Assets (0.53) | Return On Equity (1.04) |
The market value of Alterity Therapeutics is measured differently than its book value, which is the value of Alterity that is recorded on the company's balance sheet. Investors also form their own opinion of Alterity Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Alterity Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alterity Therapeutics' market value can be influenced by many factors that don't directly affect Alterity Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alterity Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alterity Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alterity Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.